MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Home・Akcijų sąrašas・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

21.47 0.05

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.46

Max

21.47

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.6M -21M
Pardavimai	14M 54M
Pelno marža	-39.611
Darbuotojai	178
EBITDA	-3.8M -23M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-2.84% downside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1B 2.2B
Ankstesnė atidarymo kaina	21.42
Ankstesnė uždarymo kaina	21.47

Naujienos nuotaikos

By Acuity

50%

185 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

6.26 / 7.47 Palaikymas ir pasipriešinimas

Day One Biopharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-10 17:04; UTC

Pagrindinės rinkos jėgos

FDA Rejects Replimune's Melanoma Drug for a Second Time

2026-04-11 00:00; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Big Yachts, Big Bucks -- Barrons.com

2026-04-10 21:55; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

2026-04-10 21:01; UTC

Uždarbis

Cango Inc.: Files Annual Report on Form 20-F With SEC

2026-04-10 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-04-10 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-04-10 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-04-10 20:31; UTC

Rinkos pokalbiai

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

2026-04-10 20:10; UTC

Įsigijimai, susijungimai, perėmimai

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

2026-04-10 19:15; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-04-10 19:15; UTC

Rinkos pokalbiai

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

2026-04-10 19:08; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-10 19:08; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures End Week Lower -- Market Talk

2026-04-10 18:38; UTC

Rinkos pokalbiai

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

2026-04-10 18:25; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Precious Metals Finish With Weekly Gains -- Market Talk

2026-04-10 18:05; UTC

Rinkos pokalbiai

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

2026-04-10 17:31; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

2026-04-10 17:26; UTC

Uždarbis

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

2026-04-10 17:10; UTC

Rinkos pokalbiai

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

2026-04-10 17:00; UTC

Svarbiausios naujienos

Construction Business Taking a Hit From Iran Conflict -- WSJ

2026-04-10 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-04-10 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-10 16:12; UTC

Uždarbis

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

2026-04-10 16:11; UTC

Uždarbis

Partners Group: Traditional Programs Contributed $3.3B

2026-04-10 16:10; UTC

Uždarbis

Partners Group: $5B of New Commitments Came From Bespoke Solutions

2026-04-10 16:10; UTC

Uždarbis

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

2026-04-10 16:10; UTC

Uždarbis

Partners Group 1Q New Client Demand $8.3B

2026-04-10 16:09; UTC

Uždarbis

Partners Group Continued to See Positive Fundraising Momentum in 1Q

2026-04-10 15:54; UTC

Įsigijimai, susijungimai, perėmimai

Plenitude Completes Acquisition of Acea Energia

2026-04-10 15:38; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Day One Biopharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

-2.84% į apačią

12 mėnesių prognozė

Vidutinis 20.86 USD -2.84%

Aukščiausias 21.5 USD

Žemiausias 17 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Day One Biopharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Day One Biopharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

6.26 / 7.47Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

185 / 348 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.